GLP-1s, rapid weight loss, and tendon or joint health: what's known

Every article on this site so far has focused on muscle. Tendons, ligaments, and joints are a related but different question, and it is one that gets asked more with every year GLP-1 medications stay in wide use: if you lose a large amount of weight quickly, does the connective tissue holding you together keep up?

The honest answer is that this is an emerging area, not a settled one. Some of what is known is genuinely reassuring. Some of it is extrapolated from other rapid-weight-loss contexts, not GLP-1 users specifically. And a small amount is preliminary data that has not yet been through peer review. This article tries to keep those three categories clearly separate.

The joint-loading upside is well established

Start with the good news, because it is easy to lose sight of it in a discussion about risk. Carrying less body weight means less mechanical load on weight-bearing joints, and this relationship has been measured directly. In a study of 142 older adults with knee osteoarthritis who completed an 18-month diet-and-exercise trial, researchers used 3D gait analysis to measure the forces moving through the knee while walking. Each kilogram of body weight lost was associated with about a 40.6-newton reduction in compressive force on the knee, roughly a fourfold reduction in load relative to the amount of weight lost.¹

That relationship compounds over thousands of steps a day. For someone with knee osteoarthritis or early joint wear, the weight loss a GLP-1 produces is, mechanically, a genuine break for the joint. This part of the picture is not in question.

What rapid weight loss can do to connective tissue, generally

Tendons and ligaments are different tissue from cartilage and bone, and they depend heavily on collagen, the structural protein that gives connective tissue its tensile strength. Collagen turns over slowly, and there is real evidence that fast, large-scale weight loss can outpace it. The clearest data comes not from GLP-1 users but from bariatric surgery patients. In a study of skin samples taken during body-contouring procedures roughly 20 months after surgery, following an average weight loss of about 132 pounds, histological analysis found poorly organized collagen structure, elastin degradation, and scarring in tissue that looked normal on the surface.⁵

That study looked at skin, not tendon, and bariatric surgery is a different intervention than a GLP-1 medication. The extrapolation is reasonable, since both produce large, fast reductions in body mass and both would be expected to place similar demands on collagen turnover throughout the body, but it is an extrapolation, not a direct finding. Nobody has published a comparable histological study of tendon tissue in GLP-1 users.

What has actually been measured in GLP-1 users' bones and joints

The most solid, peer-review-adjacent data point specific to GLP-1 users and the skeleton comes from a large retrospective cohort study presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons. Researchers matched 73,483 patients with type 2 diabetes and obesity who were treated with a GLP-1 receptor agonist to controls, balancing for age, sex, race, BMI, HbA1c, tobacco use, and comorbid conditions including chronic kidney disease and baseline osteoporosis. After five years, GLP-1 users showed a significantly higher risk of osteoporosis (4.1 percent versus 3.2 percent; risk ratio 1.29), gout (7.4 percent versus 6.6 percent; risk ratio 1.12), and osteomalacia (0.2 percent versus 0.1 percent; risk ratio 2.55), all statistically significant.²

That study is about bone, not tendon, and it was presented at a conference rather than published as a peer-reviewed article, so it should be read as an early, credible signal rather than a settled finding. But it does establish something concrete: in a large, carefully matched population, GLP-1 use tracked with higher rates of at least one category of skeletal complication over five years. Whether a similar pattern holds for tendon tissue specifically is exactly the open question this article is about.

What has, and has not, been studied about tendons specifically

A separate analysis, also presented at the 2026 AAOS meeting and using a different national health-record database, reported statistically significant, moderately higher rates of rotator cuff, Achilles, and pectoralis major tendon ruptures among GLP-1 users with obesity compared with matched non-users, tracked over five years. Absolute rupture rates remained low in both groups. As with the bone-health study above, this is conference-presented data that has not yet completed peer review, and the researchers themselves described it as showing an association, not proof that the medication causes the injuries.⁶

Set against that, two smaller peer-reviewed studies looking specifically at surgical outcomes in people who already had a tendon injury found no evidence that GLP-1 use makes things worse, and some evidence it may help. In a study of 337 patients who underwent surgical repair of a ruptured Achilles tendon, GLP-1 users had a significantly lower risk of wound infection than non-users (odds ratio 0.19), with numerically lower rates of blood clots, hospital readmission, and reintervention that did not reach statistical significance.³ In a separate matched-cohort study of arthroscopic rotator cuff repair, GLP-1 users had significantly lower 90-day hospital readmission (2.7 percent versus 3.6 percent) and lower rates of needing a second rotator cuff repair within two years (4.5 percent versus 5.7 percent), with no meaningful difference in infection, pneumonia, blood clots, or emergency visits.⁴

At the cellular level, one 2026 laboratory study found that liraglutide, an older GLP-1 receptor agonist, reduced inflammation and cell stress in tendon cells and improved biomechanical healing strength in a rat model of rotator cuff injury, working through a GLP-1 receptor pathway distinct from the drug's effect on appetite.⁷ That is an animal and bench study, not evidence about injury risk in people, but it is a reminder that GLP-1 receptors exist in tendon tissue itself and their effects there are not automatically harmful.

Plausible mechanisms, none confirmed

Researchers behind the tendon-rupture finding proposed a few mechanisms worth naming, while being clear that none has been directly tested. Appetite suppression and, in some patients, gastroparesis can reduce protein and micronutrient intake, and connective tissue depends on both for repair. Rapid loss of muscle mass can change how load is distributed across a joint, potentially straining the tendons around it. And feeling lighter and more capable can lead people to increase activity faster than their tendons have adapted to the new demand, a pattern seen in other rapid-weight-loss and post-surgical populations as well, independent of any medication.

None of these explanations has been isolated as the actual cause in a controlled study. They are reasonable hypotheses that also happen to point toward the same practical response: eat enough protein, and progress training gradually rather than all at once.

What actually protects your tendons and joints

The two levers with the strongest evidence for muscle preservation on a GLP-1 apply just as directly here, for the same underlying reason: tendons, like muscle, adapt to progressive mechanical loading and require adequate protein to remodel. See our guide to the best exercises to preserve muscle for the movement patterns that matter most, and our breakdown of training without a gym if equipment access is the barrier. The common thread in both is progression: increasing load, volume, or difficulty gradually rather than jumping back into activity all at once as the weight comes off, which is the one precaution suggested by the mechanisms above even though it has not been tested in a dedicated trial.

Our No-Gym Plan mini-guide walks through a twelve-week progression ladder built around exactly this principle: five movement patterns loaded and advanced step by step, rather than restarted at full intensity.

What the evidence does not say

Several honest limits apply here. No prospective, peer-reviewed trial has been designed specifically to measure tendon or ligament injury risk in GLP-1 users; the strongest tendon-rupture signal available is a conference presentation that has not completed peer review, and its authors describe it as an association, not a demonstrated cause. The bone-health findings on osteoporosis, gout, and osteomalacia are similarly conference-presented rather than published in a peer-reviewed journal as of this writing. The connective-tissue and collagen research cited here comes from bariatric surgery patients, not GLP-1 users, and is an extrapolation based on both interventions producing large, fast weight loss, not a direct finding about GLP-1s. And the surgical-outcomes studies that found no increased risk, or even a benefit, were conducted in people who had already sustained a tendon injury requiring surgery, a different question from whether GLP-1 use raises the odds of that injury happening in the first place. Taken together, this is a real, open question with early, mixed, and mostly preliminary evidence, not a settled risk.

The bottom line

Rapid weight loss is unambiguously good news for your joints in the purely mechanical sense: less body mass means less compressive force with every step. Whether it carries a meaningful cost for tendons specifically is a genuinely open question, supported by one preliminary, not-yet-peer-reviewed signal on tendon ruptures, one peer-reviewed and more firmly established signal on bone-related complications, and reassuring, though narrower, surgical-outcomes data on the tendon side. Until dedicated trials exist, the same two habits that protect muscle, resistance training progressed gradually and adequate protein, are also the most defensible way to support tendons and joints through the transition.

Frequently asked